ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Cardiovascular Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

18,021Medicare Part D Prescriptions Filled, Including Refills

Rank: 1 out of 323

$1.27M Total Retail Price of All Prescriptions

Rank: 1 out of 323

1,492 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
18% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Indiana
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

1% of this provider’s 1,492 patients filled at least one prescription for a schedule three drug, compared to an average of 1%.

Risky Drugs to Seniors

0% of this provider’s 16,489 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

29% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$70 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

12 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Indiana
SIMVASTATIN 968 891 1 4
CLOPIDOGREL 941 839 2 9
WARFARIN SODIUM 903 869 3 5
FUROSEMIDE 881 793 4 6
AMLODIPINE BESYLATE 867 810 5 7
LISINOPRIL 799 753 6 2
METOPROLOL TARTRATE 744 666 7 3
CARVEDILOL 584 491 8 1
PLAVIX 536 491 9 12
PROPAFENONE HCL 518 485 10 10 44
ATORVASTATIN CALCIUM 493 453 11 10
KLOR-CON M20 432 404 12 24
RANEXA 402 362 13 30
COUMADIN 375 364 14 35
ISOSORBIDE MONONITRATE ER 363 321 15 11
METOPROLOL SUCCINATE 333 316 16 8
CRESTOR 301 280 17 14
POTASSIUM CHLORIDE 279 247 18 20
RAMIPRIL 278 265 19 23
PANTOPRAZOLE SODIUM 272 236 20 43
SOTALOL 250 234 21 32
TIKOSYN 248 248 22 78
LOSARTAN POTASSIUM 242 242 23 17
DIGOXIN 222 189 24 15
NIASPAN 219 192 25 38
SPIRONOLACTONE 213 186 26 19
LEVOTHYROXINE SODIUM 210 173 27 28
MIDODRINE HCL 194 177 10 28 94
ZETIA 193 189 29 25
BYSTOLIC 180 166 30 34
ATENOLOL 179 167 31 16
NITROSTAT 178 146 32 21
AMIODARONE HCL 175 155 33 22
MULTAQ 152 151 34 46
PRADAXA 149 138 35 26
TORSEMIDE 128 116 36 47
PRAVASTATIN SODIUM 118 99 37 13
DIOVAN 114 102 38 27
BISOPROLOL FUMARATE 103 102 39 66
VYTORIN 99 99 40 57
HYDROCHLOROTHIAZIDE 94 88 41 18
CLONIDINE HCL 92 88 42 41
NITROGLYCERIN PATCH 81 63 43 39
OMEPRAZOLE 78 68 44 31
TRICOR 78 55 44 59
DILTIAZEM HCL 73 72 46 70
BENICAR 72 72 47 76
HYDRALAZINE HCL 68 61 48 36
KLOR-CON 10 67 54 49 69
ZOLPIDEM TARTRATE 65 60 50 72
BENICAR HCT 65 65 50 108
LISINOPRIL-HYDROCHLOROTHIAZIDE 65 53 50 37
FENOFIBRATE 60 43 53 49
LIPITOR 60 60 53 58
ACEBUTOLOL HCL 58 51 55 141
EFFIENT 57 57 56 42
BENAZEPRIL HCL 57 57 56 68
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 15, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.